LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Erlotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3031 | 3772 | 0.8036 | 0.7008 |
| SK-BR-3 | Erlotinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3317 | 3772 | 0.8794 | 0.8187 |
| SK-BR-3 | Erlotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 3425 | 3772 | 0.9078 | 0.8614 |
| SK-BR-3 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3339 | 3772 | 0.8853 | 0.8275 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3282 | 3772 | 0.8701 | 0.8042 |
| SK-BR-3 | Erlotinib | 10 | uM | LJP5 | 72 | hr | 1476 | 1857 | 3772 | 0.4925 | 0.1848 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3433 | 3643 | 0.9426 | 0.9113 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2989 | 3643 | 0.8190 | 0.7123 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2550 | 3643 | 0.6974 | 0.5110 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 72 | hr | 1476 | 2219 | 3643 | 0.6082 | 0.3624 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1476 | 2026 | 3643 | 0.5559 | 0.2724 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 72 | hr | 1476 | 1677 | 3643 | 0.4600 | 0.0996 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3812 | 3772 | 1.0103 | 1.0146 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 3935 | 3772 | 1.0433 | 1.0635 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 4087 | 3772 | 1.0835 | 1.1221 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 3942 | 3772 | 1.0451 | 1.0661 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3802 | 3772 | 1.0079 | 1.0111 |
| SK-BR-3 | Nilotinib | 10 | uM | LJP5 | 72 | hr | 1476 | 2005 | 3772 | 0.5313 | 0.2525 |
| SK-BR-3 | JNK-9L | 0.04 | uM | LJP6 | 72 | hr | 1476 | 2608 | 3643 | 0.7144 | 0.5407 |
| SK-BR-3 | JNK-9L | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2715 | 3643 | 0.7461 | 0.5970 |
| SK-BR-3 | JNK-9L | 0.37 | uM | LJP6 | 72 | hr | 1476 | 2457 | 3643 | 0.6730 | 0.4722 |
| SK-BR-3 | JNK-9L | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1619 | 3643 | 0.4443 | 0.0710 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1380 | 3643 | 0.3802 | -0.0497 |
| SK-BR-3 | JNK-9L | 10 | uM | LJP6 | 72 | hr | 1476 | 1203 | 3643 | 0.3309 | -0.1460 |
| SK-BR-3 | PD0325901 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 3408 | 3772 | 0.9038 | 0.8561 |